Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of thalidomide-containing induction and maintenance versus standard VAD/interferon in multiple myeloma
ISRCTN06413384Phase 3Completed
- Sponsor
- HOVON
- Start
- Nov 2001
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide, doxorubicin, dexamethasone, vincristine, melphalan and 1 more in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Nov 2001; status: completed.
02
Drugs
thalidomidedoxorubicindexamethasonevincristinemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN06413384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN06413384.